Research Article
Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
Table 1
Patients’ characteristics at baseline. NCSLC = non-small cell lung cancer; ECOG PS = Eastern Cooperative Oncology Group performance status; GI = gastrointestinal; TKI = tyrosine kinase inhibitor; RMH = Royal Marsden Hospital.
| | Characteristic | (%) |
| | Sex | | | Male | 19 (35) | | Female | 36 (65) | | ECOG PS | | | 0 | 36 (65) | | 1 | 19 (35) | | >1 | — | | Tumour type | | | NSCLC | 18 (33) | | Upper GI cancer | 11 (20) | | Bladder cancer | 8 (15) | | Renal cell carcinoma | 8 (15) | | Breast cancer | 7 (13) | | Colorectal cancer | 2 (4) | | Ovarian cancer | 1 (2) | | Therapy | | | Anti-PD-1 | 22 (40) | | Anti-PD-L1 | 26 (47) | | Anti-PD-L1 plus TKI | 7 (13) | | RMH prognostic score | | | 0 | 31 (56) | | 1 | 19 (35) | | 2 | 3 (5) | | 3 | 2 (4) | | | Median (range) | | Age | 61 (40–80) | | Number of metastatic sites | 2 (1–4) | | Number of previous treatment lines | 1 (1–6) |
|
|
